Synlogic’s dreams have gone up in smoke on the news that a pivotal phase 3 study of its lead phenylketonuria (PKU) drug is on track to miss its primary endpoint.
RESEARCH TRIANGLE PARK, N.C., July 11, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite„¢ has been chosen by Synlogic, (Nasdaq:...
Synlogic has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SYNB1934 to treat phenylketonuria (PKU), a rare inherited metabolic disease.
Biotech’s layoff sinkhole keeps growing, this time pulling in SQZ Biotechnologies and Synlogic, two Massachusetts companies that have also dropped pipeline programs to stay afloat.
Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.
Synlogic, Inc., a clinical-stage biotechnology company, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to SYNB1353 for the potential treatment of homocystinuria (HCU).
Gout is a complex form of inflammatory arthritis that occurs when excess uric acid in the body forms crystals in the joints. Patients experience symptoms such as intense joint pain, inflammation and redness, and limited range of motion in the affected joints. Current treatment options present limitations in both safety and efficacy, highlighting a need for new approaches. In addition, gout is a recognized risk factor in chronic kidney disease. SYNB2081 is a Synthetic Biotic designed to lower uric acid.
CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of new data from the company's clinical development program for phenylketonuria (PKU) during the 14th International Congress of Inborn Errors of Metabolism Meeting being held in Sydney, Australia November 21-24, 2021.
CAMBRIDGE, Mass. and BOSTON, Nov. 9, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the nomination of SYNB1353, an investigational Synthetic BioticTM medicine for the treatment of homocystinuria (HCU). SYNB1353 is the first product developed through a research collaboration between Synlogic and Ginkgo and the first investigational medicine developed on Ginkgo's platform to enter IND-enabling studies. Synlogic expects to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for SYNB1353 and begin clinical development in 2022.
CAMBRIDGE, Mass., Oct. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in Nature of preclinical research with live biotherapeutic products designed using the Company's Synthetic Biotic™ platform. In the study, a live biotherapeutic product modulated the tumor microenvironment and increased susceptibility to immunotherapy in a murine model. The research was led by Synlogic collaborators and Professor Roger Geiger of the Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.